Primary source: View printed version (PDF)
The FDA has provided specific recommendations for the development of container closure systems and device constituent parts for biosimilar products, including the need for user interface evaluations.
Ensuring the safety and efficacy of biosimilar products is critical, particularly as differences in delivery systems can introduce new risks. Adhering to this guidance helps mitigate potential user errors and device-related adverse events.
Stakeholders involved in biosimilar product development must review the draft guidance, focus on comparative safety assessments, and submit relevant comments by the deadline of October 2, 2026.
Regulatory Intelligence Lead
Review before 2026-10-02.
Named sections on product quality considerations for CCS and delivery devices, expectations for user interface evaluation (human factors studies), and data requirements for demonstrating that differences in the device do not impact safety or efficacy for the intended user population.
Pharmacovigilance and clinical safety teams must review the guidance to ensure that comparative safety assessments for biosimilar delivery devices adequately address potential user errors and device-related adverse events. For interchangeable products, specific attention is required for the user interface to ensure that switching from the reference product does not introduce new safety risks. Sponsors should update their development protocols and RMPs to include these comparative device assessments.
Stakeholders involved in biosimilar product development must review the draft guidance, focus on comparative safety assessments, and submit relevant comments by the deadline of October 2, 2026.
The FDA released a draft guidance for industry entitled 'Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts.' The draft outlines expectations for developing container closure systems and delivery devices for biosimilar and interchangeable products. It specifies that comparative assessments should ensure safety and effectiveness, especially focusing on the user interface in case of differences from reference products. Stakeholders must submit comments by October 2, 2026.
What changed: The FDA has provided specific recommendations for the development of container closure systems and device constituent parts for biosimilar products, including the need for user interface evaluations.
Why it matters: Ensuring the safety and efficacy of biosimilar products is critical, particularly as differences in delivery systems can introduce new risks. Adhering to this guidance helps mitigate potential user errors and device-related adverse events.
Practical implication: Stakeholders involved in biosimilar product development must review the draft guidance, focus on comparative safety assessments, and submit relevant comments by the deadline of October 2, 2026.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
